Literature DB >> 23685355

Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma.

Jena Hudson1, Eric Duncavage, Anna Tamburrino, Paolo Salerno, Liqiang Xi, Mark Raffeld, Jeffrey Moley, Rebecca D Chernock.   

Abstract

MicroRNAs are a primordial mechanism of gene expression control that appear to be crucial to cellular development and may play an important role in tumor development. Much is known about the genetics of medullary thyroid carcinomas, as approximately 25% are hereditary and harbor germ line activating mutations in the RET gene. Somatic RET mutations are also seen in roughly 50% of sporadic medullary thyroid carcinomas. Few studies, however, have evaluated the role of microRNA expression in these tumors. DNA and RNA were extracted from formalin-fixed paraffin-embedded tissue blocks of 15 medullary thyroid carcinomas [10 with RET mutations (3 hereditary) and 5 without RET mutations] and 5 non-tumor thyroid glands. miRNA expression of 754 targets was quantitated by real-time PCR using the ABI OpenArray miRNA assay. Three miRNAs showed significant differential expression and were validated in a larger cohort of 59 cases by real-time PCR. Expression of potential downstream targets and upstream regulators was also investigated by real-time PCR. miR-375 and miR-10a were significantly overexpressed, while miR-455 was underexpressed in medullary thyroid carcinomas. Expression of all 3 miRNAs was validated in the larger cohort of cases (miR-375, p=3.3×10(-26); miR-10a, p=5.6×10(-14); miR-455, p=2.4×10(-4)). No significant differences in miRNA expression were found between RET mutation positive and negative tumors nor between sporadic and hereditary tumors. Expression of the potential downstream targets of miR-375, YAP1 (a growth inhibitor) and SLC16a2 (a transporter of thyroid hormone), was down-regulated in the tumors suggesting that miR-375 is a negative regulator of the expression of these genes. Thus, differential expression of miR-375, miR-10a and miR-455 may be important for tumor development and/or reflect C-cell lineage of medullary thyroid carcinoma. Furthermore, the growth inhibitor YAP1 is identified as a potential important downstream target of miR-375.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Medullary thyroid carcinoma; YAP1; miR-10a; miR-375; miR-455; microRNA

Mesh:

Substances:

Year:  2013        PMID: 23685355      PMCID: PMC3712278          DOI: 10.1016/j.yexmp.2013.05.001

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  33 in total

1.  MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms.

Authors:  Yan Zeng; Rui Yi; Bryan R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-05       Impact factor: 11.205

2.  Medullary carcinoma.

Authors:  J Albores-Saavedra; V A LiVolsi; E D Williams
Journal:  Semin Diagn Pathol       Date:  1985-05       Impact factor: 3.464

3.  Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals.

Authors:  Xiaohui Xie; Jun Lu; E J Kulbokas; Todd R Golub; Vamsi Mootha; Kerstin Lindblad-Toh; Eric S Lander; Manolis Kellis
Journal:  Nature       Date:  2005-02-27       Impact factor: 49.962

4.  MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets.

Authors:  Deepak Abraham; Nicole Jackson; Justin S Gundara; JingTing Zhao; Anthony J Gill; Leigh Delbridge; Bruce G Robinson; Stan B Sidhu
Journal:  Clin Cancer Res       Date:  2011-05-27       Impact factor: 12.531

5.  Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

Authors:  F D Gilliland; W C Hunt; D M Morris; C R Key
Journal:  Cancer       Date:  1997-02-01       Impact factor: 6.860

6.  miR-15a and miR-16-1 down-regulation in pituitary adenomas.

Authors:  Arianna Bottoni; Daniela Piccin; Federico Tagliati; Andrea Luchin; Maria Chiara Zatelli; Ettore C degli Uberti
Journal:  J Cell Physiol       Date:  2005-07       Impact factor: 6.384

7.  miR-375 maintains normal pancreatic alpha- and beta-cell mass.

Authors:  Matthew N Poy; Jean Hausser; Mirko Trajkovski; Matthias Braun; Stephan Collins; Patrik Rorsman; Mihaela Zavolan; Markus Stoffel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

Review 8.  Targeting the RET pathway in thyroid cancer.

Authors:  Samuel A Wells; Massimo Santoro
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

9.  Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

Authors:  Junichi Takamizawa; Hiroyuki Konishi; Kiyoshi Yanagisawa; Shuta Tomida; Hirotaka Osada; Hideki Endoh; Tomoko Harano; Yasushi Yatabe; Masato Nagino; Yuji Nimura; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

10.  Suppression of non-small cell lung tumor development by the let-7 microRNA family.

Authors:  Madhu S Kumar; Stefan J Erkeland; Ryan E Pester; Cindy Y Chen; Margaret S Ebert; Phillip A Sharp; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

View more
  46 in total

Review 1.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

2.  MicroRNA-15b/16 Attenuates Vascular Neointima Formation by Promoting the Contractile Phenotype of Vascular Smooth Muscle Through Targeting YAP.

Authors:  Fei Xu; Abu Shufian Ishtiaq Ahmed; Xiuhua Kang; Guoqing Hu; Fang Liu; Wei Zhang; Jiliang Zhou
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-08-20       Impact factor: 8.311

3.  Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion.

Authors:  Tomohiro Umezu; Satoshi Imanishi; Seiichiro Yoshizawa; Chiaki Kawana; Junko H Ohyashiki; Kazuma Ohyashiki
Journal:  Blood Adv       Date:  2019-11-12

Review 4.  Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes.

Authors:  Maryam Zarkesh; Azita Zadeh-Vakili; Fereidoun Azizi; Forough Foroughi; Maziar Mohammad Akhavan; Mehdi Hedayati
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

Review 5.  Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.

Authors:  Ying-Hsia Chu; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

Review 6.  Noncoding RNAs in endocrine malignancy.

Authors:  Jessica Kentwell; Justin S Gundara; Stan B Sidhu
Journal:  Oncologist       Date:  2014-04-09

7.  MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical-pathological features and outcome.

Authors:  Francesca Galuppini; Loris Bertazza; Susi Barollo; Elisabetta Cavedon; Massimo Rugge; Vincenza Guzzardo; Diana Sacchi; Sara Watutantrige-Fernando; Federica Vianello; Caterina Mian; Gianmaria Pennelli
Journal:  Virchows Arch       Date:  2017-08-31       Impact factor: 4.064

8.  Cancer stem cells as a potential therapeutic target in thyroid carcinoma.

Authors:  Luisa Vicari; Cristina Colarossi; Dario Giuffrida; Ruggero De Maria; Lorenzo Memeo
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

Review 9.  Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease.

Authors:  Melanie A Felmlee; Robert S Jones; Vivian Rodriguez-Cruz; Kristin E Follman; Marilyn E Morris
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

10.  The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms.

Authors:  Esther Diana Rossi; Tommaso Bizzarro; Maurizio Martini; Sara Capodimonti; Diletta Sarti; Tonia Cenci; Mirna Bilotta; Guido Fadda; Luigi Maria Larocca
Journal:  Endocrine       Date:  2016-01-27       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.